“The best course of action would be to eliminate ODP altogether. However, to the extent that is not feasible, there is an ...
The U.S. Court of Appeals for the Federal Circuit (CAFC) reversed a district court’s decision in Snaprays (dba SnapPower), v. Light Defense Group (LDG) on May 2, finding that Lighting Defense Group ...
Benoit Poyet is a senior industrial property attorney, specialized in patents, and president of the AtlantIP International firm. He operates in cross-disciplinary fields including engineering ...
A client’s recent experience applying for a European patent led to the development of a possible optimization strategy to address patent costs for clients. This client had made an initial U.S. filing ...
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today vacating and remanding with ...
“Using section 1498 would not significantly reduce drug costs because, as courts have repeatedly recognized, the law requires the government to provide ‘reasonable and entire compensation’ for any ...
The U.S. Patent and Trademark Office (USPTO) recently released new guidance for practitioners using artificial intelligence ...
“[T]he Federal Circuit noted that questions about a party’s ability to license patent rights do not provide a reasonable ...
Expansion to FTC’s Orange Book Campaign Leads to Calls for More Clarity from Pharmaceutical Industry
On April 30, the Federal Trade Commission (FTC) announced that it was expanding its campaign against allegedly improper patent listings in the U.S. Food & Drug Administration’s (FDA) Orange Book.
“The stated goal of facilitating commercialization in particular may seem contradictory to some, considering the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results